Sulfur

DERMATOLOGICALS

Key facts

Sulfur is a drug catalogued in DrugCentral. It was first approved by the FDA in 1940. DrugCentral lists 2 molecular targets, including CA1 and CA2. Recorded indications include Acne vulgaris, Acneiform eruption, Acute necrotizing ulcerative gingivitis and Aphthous ulcer of mouth.

• Molecular targets: CA1 and CA2 (2 listed in DrugCentral).
• Indications: Acne vulgaris, Acneiform eruption, Acute necrotizing ulcerative gingivitis, Aphthous ulcer of mouth and Greasy skin and others.
• ATC code: D10AB02 (Preparations containing sulfur).
• Molecular formula: S; molecular weight 32.07 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Acne vulgaris
• Acneiform eruption
• Acute necrotizing ulcerative gingivitis
• Aphthous ulcer of mouth
• Greasy skin
• Pityriasis simplex
• Seborrheic dermatitis

Off-label uses (2)

• Itching of skin
• Rosacea

Contraindications (20)

• Adrenal cortical hypofunction
• Anemia due to enzyme deficiency
• Atrophoderma
• Blister
• Conduction disorder of the heart
• Condyloma acuminatum
• Decreased respiratory function
• Deficiency of glucose-6-phosphate dehydrogenase
• Denuded skin
• Diabetes mellitus
• Eruption of skin
• Erythroderma
• Infection of skin AND/OR subcutaneous tissue
• Inflammatory dermatosis
• Kidney disease
• Open wound
• Peripheral vascular disease
• Seizure disorder
• Skin irritation
• Telangiectasia disorder

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Carbonic anhydrase 1	CA1	unknown	Ki 6.22
Carbonic anhydrase 2	CA2	unknown	Ki 4.40

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1940-09-17	FDA	—	POYTHRESS

ATC classification

ATC code	Therapeutic hierarchy
D10AB02	DERMATOLOGICALS › ANTI-ACNE PREPARATIONS › ANTI-ACNE PREPARATIONS FOR TOPICAL USE › Preparations containing sulfur

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Joint dislocation	222.3
Seronegative arthritis	167.3
Joint stiffness	160.2
Prescribed underdose	141.5
Wound infection	111.4
Visual impairment	110.4
Psoriasis	110.2
Walking aid user	109.7
Lupus vulgaris	107.2
Retinitis	107.1
Osteoporosis	105.4
Laryngitis	99.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Sulfur is on its molecule page.

• Molecular formula: S
• Molecular weight: 32.07 g/mol
• CAS number: —
• InChIKey: NINIDFKCEFEMDL-UHFFFAOYSA-N
• PubChem CID: 5362487

[S]

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sulfur used for?

DrugCentral lists the following indications for Sulfur: Acne vulgaris, Acneiform eruption, Acute necrotizing ulcerative gingivitis, Aphthous ulcer of mouth, Greasy skin, Pityriasis simplex and Seborrheic dermatitis.

How does Sulfur work?

Its molecular targets in DrugCentral include CA1 and CA2.

When was Sulfur first approved?

Sulfur was first approved by the FDA in 1940.

What is the chemical formula of Sulfur?

Sulfur has the molecular formula S and a molecular weight of 32.07 g/mol.

Sources

• DrugCentral drug card 4260 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1235452 — compound record and bioactivity
• PubChem CID 5362487 — chemical identifiers
• FDA UNII 70FD1KFU70 — substance identity
• DailyMed: FDA labels for Sulfur — current prescribing information (label search)
• UniProt P00915 (CA1) — target protein
• UniProt P00918 (CA2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.